Discovery of Quinazolinone Derivatives as Potent PARP1 Inhibitors
Abstract
Poly-(ADP-ribose) polymerase 1 (PARP1) is the most abundant and well-characterized member of PARP family and plays a significant role in DNA damage detection and repair. Cancer cells with homogeneous recombination deficiency (HRD) depend on PARP1 mediated DNA repair for survival, which makes PARP1 as a potential cancer treatment target. This patent highlights the synthesis and pharmaceutical composition of novel quinazolinone based PARP inhibitors for cancer treatment.
Fields of Study & Subjects
PARP inhibition in cancer therapy
Synthesis and bioactivity of alkaloids
Signaling Pathways in Disease
Publication details
- Journal / source
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Volume
- 17
- Issue
- 2
- Pages
- 282–283
- Publication date
- 13 January 2026
- Language
- EN